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Dr. Don St. Germain

MESSAGE FROM
THE DIRECTOR
Dear Friends,
Each year as the foliage is starting to garner our attention and as our fiscal year is coming to a close, I give a State of
the Institute presentation to our faculty and staff. The presentation focuses on institutional and individual successes,
opportunities going forward, and challenges old and new. Not surprisingly, part of the presentation is a report on the
grant funding the Institute has received during the prior 12 months. It is the nature of our business that extramural
funding ebbs and flows from month to month and year to year as new grants are awarded and older ones expire.
Thus, there are good years and there are lean years — and then there is 2017.
The year just ended is the most remarkable funding year in the history of MMCRI. Through the hard work of our
investigators, technical staff, administrative staff, and collaborators, MMCRI was awarded over $39 million in grants
in 2017. These funds will serve to support our research activities with the goals of improving the care of our patients
and our communities and advancing the science of medicine. Much of this funding came from two large federal
grants of $20 million and $11 million, and three awarded by foundations/non-profit organizations.
This funding will advance research in chronic diseases such as cardiovascular, addiction, aging, and cancer, as well as
metabolic diseases that include obesity and diabetes. In my recent address, I was anxious to acknowledge the
principal investigators and research teams responsible for those major awards. But prior to that celebration, I chose
to recognize one of our junior investigators, Michaela Reagan, and our Vector-borne Laboratory for their
accomplishments in being awarded the smallest grants in 2017, each for about $2,000. Although comparably small in
amount, each grant grew out of the same scientific drive, intellectual curiosity and dedication shown by those
working on the largest grants in our portfolio. Each award, no matter the size, better positions us to accomplish our
mission.
The pages that follow highlight the work underway from these research awards, and much more. I hope you enjoy
taking a closer look at the research and the individuals taking on this exciting work. I extend my admiration and
congratulations to all for helping make 2017 a year of wonderful accomplishments.
Sincerely,
Don St. Germain, MD, Director & Vice President of Research
Maine Medical Center Research Institute
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MMCRI

At A Glance

2017 Leadership
Executive Administration
Donald St. Germain, MD
Director & VP Research
Rick McAllister, MEd
Senior Director, Research Administration

Center Leadership
Above: 81 Research Drive, Scarborough, Maine.

Thomas Gridley, PhD
Interim Director, Center for Molecular Medicine
Paul Han, MD, MA, MPH
Director, Center for Outcomes Research & Evaluation

2017 FAST FACTS

Susan Santangelo, ScD
Director, Center for Psychiatric Research
Clifford Rosen, MD
Director, Center for Clinical & Translation Research
For a full list of Principal Investigators, Affiliated Faculty, and
Staff, please visit our website, www.mmcri.org

2017 Sources of Research Support
By Sponsor Type

180 Staff Members
$39 Million Grants Awarded
200+ Clinical Trial Studies
255 Scientific Publications
12 Core Facilities with State
of the Art Equipment (see in
depth story, page 5) and
BioBank Tissue Repository with
Over

100,000 Human

Tissue Samples Distributed
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BENCH—BASIC RESEARCH

Tom Gridley, PhD, Interim Director

Center for Molecular Medicine
Funding from NIH Helps Build
Research Excellence in Understanding
Causes of Metabolic Disease
It was an exciting
summer for
MMCRI; on the
heels of a NIH $20
million award (see
details page 6), the
Institute was
awarded a five-year,
$11 million Center
of Biomedical
Research Excellence
(COBRE) grant also
Dr. Lucy Liaw, Director of the COBRE by the National Institutes of
in Metabolic Networks
Health. This funding will establish
a multidisciplinary research center
at MMCRI to model the basis of human metabolic diseases. This
program includes partnerships between Maine Medical Center
and the University of Maine, the University of New England and
Brown University.
The COBRE program is led by Dr. Lucy Liaw, Associate Director
of the Center for Molecular Medicine, with support from Dr. Cliff
Rosen, Director of The Center for Clinical & Translational
Research at MMCRI, and Dr. Irwin Brodsky, Maine Medical
Partners Endocrinologist and Clinical Advisor. The overall goal is
to address obesity, osteoporosis and diabetes – all metabolic
diseases common in Maine – by understanding pathways that lead
to these disorders.
“One feature of this COBRE award is that it supports young
investigators as they embark upon independent research projects,”
says Dr. Liaw. The COBRE award provides funding to four young
investigators (see infographic, right) to conduct cellular, molecular,
biochemical and clinical research. Dr. Liaw adds, “We have
established a network of mentors and consultants to provide
strong support for these investigators as they launch their careers.
Fostering and maintaining talent in Maine is crucial for the
growth of biotechnology in our state.”
The award also supports the expansion of state-of-the-art
technology, including advanced protein and lipid analysis and
bone measurements, and the assessment of physiology and body
metabolism. For more details and progress of the metabolic
COBRE: www.mmcri.org/metabolic_cobre.
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BENCH—BASIC RESEARCH

Tom Gridley, PhD, Interim Director

Center for Molecular Medicine
New Federal Research
Grants: Cancer, Heart, &
Endocrine Disease
Drs. Peter Brooks, Sergey Ryzhov, and Arturo
Hernandez in the Center for Molecular Medicine
all were successful in obtaining new federal grant
funding this past year to support innovative
research projects.
Cancer & the Immune System
Peter Brooks, PhD
Peter Brooks is a cancer researcher with new
funding from both the National Institutes of
Health (NIH) and the Department of Defense
(DOD). Both projects focus on the immune
system and developing potential therapeutics that
may help the body activate its natural immune cells to
detect and destroy tumor cells. The DOD project focuses
on ovarian cancer, which has been difficult to treat with
current immunotherapies. The Brooks lab discovered
that a cancer-specific fragment of collagen seems to allow
ovarian cancer cells to hide from immune cells, and they
have developed a specific antibody that can bind and
block this collagen fragment. The project will test
whether this antibody can thus “reactivate” immune
control of ovarian cancer and assist in anti-cancer
therapies. The NIH project focuses on malignant
melanoma, for which the survival rate is still low, despite
treatment. This laboratory research is critical in the
development of new, targeted therapies with the potential
to improve the health outcomes of cancer patients.
Heart Disease
Sergey Ryzhov, PhD
Dr. Ryzhov is also studying the body’s natural immune
system, in the context of heart disease. Myocardial
infarction, or a heart attack, happens to someone in the
United States every 40 seconds. This NIH funded project
studies the growth factor neuregulin and its interaction
with its receptor, ERBB3. The Ryzhov lab discovered that
this signaling axis controls the shift of inflammatory cells
from a pro-inflammatory state to a pro-resolution state.
Early after myocardial infarction, immune cells infiltrate
to repair the heart tissue, but need to be shut down to
avoid chronic inflammation. The lab has identified
neuregulin as a factor that can promote resolution of
inflammation, which could partly explain why neuregulin
provides a beneficial effect following myocardial
infarction.

Left to right: Arturo Hernandez, Sergey Ryzhov, and Peter Brooks

Thyroid & Genetics
Arturo Hernandez, PhD
Dr. Hernandez studies the consequences of thyroid hormone
alterations during the developmental period for
neuroendocrine and neurological function in later life. His
lab focuses on the type 3 deiodinase (Dio3), a critical
enzyme that limits the levels of exposure to thyroid hormone.
The recently awarded NIH grant is based on the finding that
a developmental overexposure to thyroid hormone leads to
neurological abnormalities not only in the individuals
affected, but also in their unexposed descendants due to
mechanisms of transgenerational epigenetic inheritance.
Some of the neurological abnormalities observed include
aberrant brain morphology and cytoarchitecture,
hydrocephalus and altered mood and social behavioral
profiles of relevance to human conditions like anxiety,
depression, attention deficit and hyperactive disorder, autism
and schizophrenia. This work may partly explain the
unidentified heritable etiology of some of these conditions
and lead to novel epigenetic-based clinical tools for risk
assessment, prevention and response to clinical treatment.

PATENTS
AARON BROWN, PhD &
LEIF OXBURGH, DVM, PhD
Culture conditions for expansion of nephron
progenitor cells
VOLKHARD LINDNER, MD, PhD
Kit for detecting Cthrc1 in a sample
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High-Tech & Collaboration are Key Elements to
Physiology Core Success
“Our Core feels like more of a collaboration than a
service,” says Victoria DeMambro, Manager for
Principal Investigator Cliff Rosen’s Physiology Core
Facility at MMCRI. This atmosphere of
collaboration brings her and her colleagues a
tremendous amount of satisfaction in their efforts
to provide researchers with comprehensive, in-house
metabolic and cellular phenotyping of mouse
strains.
The Physiology Core at MMCRI, established in
2012, was championed by Dr. Rosen and others,
and developed initially in response to a new
demand in the field of Stem Cell Biology that
researchers move from cell-based assays to mouse
models to study changes in whole organism
physiology. With a focus on assessing metabolic
phenotypes for novel mouse models of human
disease, analyses from this core facility provide insight into
“on target” and “off target” tissue phenotypes, and
increase our understanding of the physiological
implications of changes in regulators of stem and
progenitor cell formation.
To complement assays for biochemical markers of skeletal
and soft tissue metabolism, sixteen high-tech Promethion
metabolic mouse cages (like the one behind DeMambro
pictured above) provide eighty-seven distinct readings on
each mouse per second - collected over the course of about
five days per experiment - on mouse activity, body
composition, oxygen consumption, CO2 production, heat
production, physical and behavioral profiles, and diet and
fluid intakes.
The Physiology Core provides this real-time data on
metabolic phenotypes to fully complement other
biochemical studies for comprehensive hematological,
metabolic, and skeletal phenotyping. This output is
coupled with dual energy X-ray absorptiometry/NMR
analysis that measures in vivo body composition in a cross

Above: Vicki DeMambro prepares for an experiment to monitor
comprehensive metabolic and behavioral features in mice.

-sectional or longitudinal manner. A recently up-graded Seahorse
XFe96 analyzer provides advanced cellular and mitochondrial
bioenergetics data, to quantify oxidative phosphorylation and
glycolysis in cells and tissues.

71

DeMambro notes many sources of
satisfaction and success from the
Physiology Core. Most important
among these are being able to
Publications from the
provide help to numerous new and
Center of Molecular
established researchers who go on to
publish their work, and helping a
Medicine in 2017.
number of early-career investigators
begin to acquire their own research
funding. Her enthusiasm is high around
the Core’s role in supporting MMCRI’s new COBRE in
Mesenchymal and Neural Regulation of Metabolic Networks grant
projects – each of which is led by an early-career MMCRI researcher.
For more information on MMCRI’s 12 core facilities and services,
please visit our website: www.mmcri.org.

Noteworthy
EVENTS
RESEARCH RETREAT – MAY 3, 2017
MMCRI and Maine Medical Center coordinated a
multidisciplinary biomedical research symposium,
bringing together more than 200 physicians, nurses,
health care providers, scientists and trainees from
over 15 hospital departments, as well as affiliate
institutions in Maine, and from neighboring states in
New England.

SEMINAR SERIES
MMCRI hosted 20 seminar guests in 2017.
DATA REVIEW SERIES
MMCRI graduate students, postdoctoral trainees,
Staff Scientists, and Core Directors delivered 32 Data
Review Sessions for their colleagues in 2017.
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BEDSIDE—CLINICAL & TRANSLATIONAL RESEARCH

Center for
Clinical & Translational Research

Cliff Rosen, MD, Director

$20M from NIH Will Establish
Northern New England Clinical &
Translational Research Network
In July, the National Institutes of Health (NIH)/National
Institute of General Medical Sciences (NIGMS) awarded a
five-year, $20 million research grant to Maine Medical
Center and its partnering institutions, the University of
Vermont and the University of Southern Maine, to
establish the Northern New England Clinical and
Translational Research Network (NNE- CTR), a
consortium dedicated to enhancing collaborative
biomedical research activities for the improvement of
human health. This consortium joins nine other
NIGMS supported regional networks across the
country.
Clifford Rosen, MD,
Director of the Center
for Clinical and
Translational
Research at
MMCRI, and Gary
Stein PhD, Director
of the University of
Vermont Cancer Center,
will co-lead the program
along with Program
Coordinators, Thomas
Gridley, PhD, (MMCRI)
and Gordon L. Jensen,
MD, PhD, (UVM).
Collaborations with researchers at Tufts University School of
Medicine and the Geisel School of Medicine at Dartmouth will
serve to extend the capabilities of the network and its reach across
the region.
The NNE-CTR aims to help researchers develop and implement
innovative medical treatments for many chronic diseases
prevalent in our region including cancer, heart disease, obesity,
diabetes, Alzheimer’s disease and substance abuse. Research
activities will also focus on defining optimal methods of disease
prevention and health care delivery in rural environments, where
approximately 60 percent of Maine’s population resides.
The network will also train the next generation of biomedical
scientists, physicians and nurses in research methodology to
attract additional research support to the region.

Dr. Gary Stein, University of Vermont (left) and Dr. Cliff Rosen
(right) briefed Senator Susan Collins on the NNE-CTR award.

Such initiatives are critical in meeting the healthcare needs of
the region’s aging population in an era when groundbreaking medical treatments are rapidly being developed.
“Our goal is to support innovative and transformative
research, increase participation in clinical research and
improve access of our rural residents to clinical studies. This
will ultimately improve the health and vitality of the people
of Maine, Vermont, and New Hampshire,” said Dr. Rosen.

54

MMC BioBank is one of only 54
biorepositories nationwide to
receive College of American
Pathologists (CAP) Accreditation.
The BioBank received its
recertification in September 2017.
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Clinical Investigator Spotlight: Dr. David Seder
SETPOINT2 is an international, multi-site
clinical trial to improve outcomes for patients
who have suffered a severe stroke by assessing
the best timing of tracheostomies. Heading this
study is Dr. David Seder, the US Principal
Investigator (Maine Medical Center), along with
Dr. Julian Bösel, the German Principal
Investigator (University of Heidelberg).
The SETPOINT2 study findings could benefit
patients because the timing of a tracheostomy
may affect the amount of sedating medications
that is required, and could affect brain recovery
and the body’s ability to return to pre-stroke
activities. Preliminary studies suggest it could be
beneficial to perform a reversible tracheostomy
procedure earlier than is usually done after
severe stroke (within the first 5 days) as opposed
to delaying more than 10 days before
performing the procedure. This $2.6 million
dollar research grant was awarded by the Patient
Centered Outcomes Research Institute
(PCORI). The name SETPOINT2 stands for
Stroke-Related Early Tracheostomy vs
Prolonged Orotracheal Intubation in
Neurocritcal Care Trial2.

The SETPOINT2 study is
committed to keeping patients
informed as well as
incorporating their insight for
the research. Through the
study’s website —
(www.setpoint2.org) and
quarterly newsletter, patients
and site investigators can learn
more about the study and its
progress. In addition, both the US and German
lead sites have Research Advisory Committees
(RAC) that meet biannually. Each RAC is made up
of former patients, caregivers, research
coordinators, program managers, clergy, and other
community support members to review the study’s
progress and give insight to help shape the research
program moving forward.
“The RAC is paramount for improving our study
and patient outcomes,” says Seder. “I am excited
about the study’s progress and are looking forward
to enrolling more patients at our 24 sites across the
US and Germany.”

Above: The US RAC meeting was
held at Maine Medical Center in
December. Dr. Seder, Principal
Investigator (back row, third from
right).

200+
Clinical Trial Studies in
2017 at MMCRI.

Vector-borne Disease Lab 2017 Update
Director, Robert Smith, MD, MPH

As climate change disrupts ecological systems,
established patterns of disease transmission by
ticks and mosquitos change. In collaboration
with the Maine Centers for Disease Control, the
Vector-borne Disease Laboratory (VBDL) at
MMCRI (with our vector ecologist Charles
Lubelczyk as Project Leader) developed a
program with two research initiatives:
1) creation of a statewide surveillance program
for mosquito-borne viruses, and 2) development
of a mosquito-rearing facility, to be used for the
monitoring of pesticide resistance in mosquitoes.
Mosquito-borne West Nile virus and Eastern
Equine Encephalitis are emerging in Maine, with
cases, including one fatality, reported for the
first time in our state during recent years.
Collaborations with several University of Maine
campuses as well as Acadia National Park and
the University of Southern Maine (Fig. 1) employ
students as field technicians, giving some their
first experience in the fields of public health and
eco-epidemiology.
The VBDL’s current research on tick borne
diseases includes risk projection based upon
climate change, studies on newly recognized
agents of disease transmitted by deer ticks, and
evaluation of a new diagnostic methodology for
Lyme disease.

By 2050, Maine is expected to be approximately
2°C warmer and 5–10% wetter than present.
Research associate and University of Maine PhD
candidate Susan Elias has gathered data to test
the hypothesis that Lyme disease in Maine is
associated with warm winters and humid
summers, in addition to focal high white-tailed
deer density, presence of invasive plant species,
and suburbanization.
Dr. Rebecca Robich and Margaret Welch
completed a survey of the presence of deer tick
virus in Maine. The VBDL is seeking to better
understand the ecological factors and human
risk factors that can lead to rare but devastating
human infections by this virus, which caused the
death of a woman in the Midcoast area.
In collaboration with Dr. Peter Krause of Yale
School of Public Health, Dr. Robert P. Smith,
VBL Director, continued a multi-year study to
better understand the pathogenesis and clinical
spectrum of tick-borne babesiosis and of a newly
recognized agent of relapsing fever, Borrelia
miyamotoi.
On the Lyme disease front, the lab initiated a
pilot project on the use of a novel diagnostic test
for early Lyme disease. Our collaborators for this
project include the Division of Infectious

Figure 1. Municipalities in Maine sampled
during the mosquito surveillance by MMCRIrelated surveys (Blue) or ME Department
of Agriculture, Conservation, and Forestry
(DACF) surveys (Green).

Diseases at Johns Hopkins and an
independent biotech company.
Lastly, if you’d like to read a
historical journey, check out the
VBDL’s co-founder Pete Rand’s
memoir, Of Ticks and Islands, which
provides a lively and personal
account of our early adventures in
the field.
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BEDSIDE—PSYCHIATRIC RESEARCH

Susan Santangelo, ScD, Director

Center for
Psychiatric Research
First of its kind, SPARK Northern New England received funding April 2017
The major focus of the Center for Psychiatric Research is
on uncovering the biological underpinnings of psychiatric
disease and behavioral dysfunction including, for example,
investigating genetic risk factors underlying
neurodevelopmental disorders such as autism. SPARK is
a landmark online research partnership designed to speed
up our understanding of the causes of
autism and how autism impacts all those
affected.
SPARK’s goals are twofold. First, the
project will identify the hundreds of
autism genes at play and link them to the
biological mechanisms that they govern,
as well as any environmental factors to
which those with autism may have been
exposed. Second, it seeks to connect these
individuals and families to research
opportunities that advance the understanding of autism.
Maine Behavioral Healthcare and MMCRI were chosen as the
clinical site for Northern New England, one of 25 clinical sites
across the nation. “SPARK is a unique opportunity for people
in Maine, New Hampshire and Vermont to participate in cutting edge research and receive results from the most advanced
genetic analysis available,” says Matthew Siegel, M.D., Principal
Investigator for SPARK Northern New England.
The study is funded by the Simons Foundation Autism
Research Initiative. This first of its kind study will be done
entirely online to encourage all in the autism community to
participate, with the goal of establishing the largest online
autism research cohort —50,000. There have been 703
participants enrolled to date in the SPARK Northern New
England study.
Since there is no singular cause of autism, there is still much we
do not know. The knowledge gained through scientific
research like SPARK is moving us closer to better understanding the causes of autism and developing effective treatments
and tools for the everyday challenges autism brings. For more
information about SPARK Northern New England see
sparkforautism.org/mainemedicalcenter.

Left: Dr. Siegel is the Principal Investigator for
SPARK Northern New England, the VP for Medical
Affairs Developmental Disorders Service Maine
Behavioral Healthcare, and a Clinical Investigator
at MMCRI.

Noteworthy

ECT’s Role in Patients
with Dementia
& Behavioral Disturbance
Dr. Rago is the Chief Resident for
Research & Quality Improvement
in Psychiatry at Maine Medical
Center (MMC). She is currently
Amanda Rago, D.O.,
the Principal Investigator on a study Principal Investigator
analyzing the efficacy and safety of
electroconvulsive therapy (ECT) in patients with dementia
and behavioral disturbance, which is taking place at the
inpatient Psychiatry Unit (P6) at MMC. The study began in
2016 and is funded by a Mentored Research Grant from
MMCRI.
“In addition to establishing the safety and efficacy of this
intervention in this population, we anticipate that data
collected in this observational study will provide insight into
which patients (with what clinical manifestations) are
predicted to have a positive response to ECT,” says Dr. Rago.
“We also hope to inform future discussion of depression in
patients with dementia.”
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Study Looks at Effects of Earthquakes
in Nepal
On April 25, 2015 a magnitude 7.8 earthquake struck Nepal,
killing more than 8,000 people and injuring over 21,000. As a
result, hundreds of thousands of Nepalese were homeless and
entire villages were flattened in many areas. Complicating
matters, on May 12, 2015 the largest aftershock occurred
(magnitude of 7.4) followed minutes later by a magnitude 6.3
shock. More than 450,000 people were displaced overall.
The horrific effects of earthquakes go far beyond immediate
physical destruction. It is difficult to imagine the losses both

Above: Maine Behavioral Healthcare Trauma experts, Rebecca
Hoffman-Frances and Rebecca Brown, lead discussion of earthquake
aftermath with school children. Right: A destroyed home in Nepal and
Nepalese family outside their temporary home.

physical and mental that can occur during such devastation.
Until now there was limited knowledge regarding postdisaster psychopathology, and even mental health in general
in the Nepali population. Through internal funding, Susan
Santangelo, the Director of the Center for Psychiatric
Research at MMCRI, was able to launch the Nepal PTSD
Project in March 2016.
“The goals of the project are to determine the prevalence of
PTSD, depression, resilience and factors associated with event impact among earthquake survivors,” says Santangelo. “In addition, we
trained college students in Skills for Psychological Recovery (SPR) to enable the students to train villagers to ultimately help each other.”
Currently, data are being analyzed to determine the impact of teaching skills for psychological recovery to the villagers.

Autism & Developmental Disorders Inpatient Research Collaborative
(ADDIRC) Update: Autism Inpatient Collection (AIC)
The Autism & Developmental Disorders Inpatient Research Collaborative (ADDIRC) is a research consortium of specialized child
psychiatry in-patient units that serve children and adolescents with autism and developmental disorders. ADDIRC was launched in
2013 and is led by Dr. Matthew Siegel and Susan Santangelo. Until recently, adequate phenotypic and biological data from
individuals severely affected by autism was lacking. Now that has changed due to the Autism Inpatient Collection (AIC) phenotypic
database and biorepository which was created by the ADDIRC and is supported by grants from the Simons Foundation Autism
Research Initiative and the Nancy Lurie Marks Family Foundation.
Highlights since the launch of ADDIRC &
AIC:


Screened 2172 inpatient youth (499
patients screened in year 4)



1158 Subjects enrolled & 911 Subjects
with ASD confirmed



Biosamples collected from 791 confirmed ASD subjects and 916 biological
parents comprising 194 singletons, 278 proband/parent duos, and 319 trios



14 total manuscripts published or in review; 16 conference posters plus 3 recent abstracts submitted

The study is scheduled to conclude October 2018. For more information about ADDIRC, AIC and a list of Coordinating &
Participating Site Members go to www.mmcri.org/cpr.
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COMMUNITY—HEALTH SERVICES RESEARCH

Center for
Outcomes Research & Evaluation
(CORE)

Paul Han, MD, MA, MPH Director

Understanding New Genomic Tumor Tests
CORE’s focus is on
conducting innovative
research to understand
and improve patientcentered outcomes in
healthcare delivery. In
2017, CORE received a
$1.5 million subcontract
to lead the outcomes
evaluation for the Maine
Cancer Genomics
Initiative (MCGI). Led by
the Jackson Laboratory
(JAX) and supported by
the Harold Alfond
Dr. Paul Han, Principal Investigator
Foundation,
the MCGI is a
for MCGI Grant & MMCRI Director
unique
collaboration
of CORE
between research and clinical
institutions to evaluate implementation of precision
medicine in oncology throughout Maine.

sequencing in community settings as precision medicine becomes
more widely adopted throughout the United States. CORE’s
multidisciplinary team on the MCGI includes Leo Waterston, MA,
Sue Miesfeldt, MD, Eric Anderson, PhD, Christine Duarte, PhD,
Lee Lucas, PhD, Kim Murray, MS, Caitlin Gutheil, MS, and
Hayley Mandeville, MPH.
“Cancer patients typically get their care at community hospitals, in
rural or suburban settings, and this is especially true in Maine,”
says Dr. Han. “The MCGI provides a unique opportunity to
understand and improve the implementation of emerging genomic
technologies in community-based settings in Maine and beyond.”

What are the key Components of MCGI?

A team at CORE, led by Principal Investigator Dr. Paul Han
(pictured above), is partnering with the MCGI team at JAX
(led by Drs. Jens Reuter & Andrey Antov), to study the
implementation of tumor genomic testing and downstream
outcomes that will inform the implementation of precision
medicine in oncology, and develop a sustainable researchhealthcare system partnership model.
The research aims of the MCGI are:


To characterize the feasibility and outcomes of
implementing tumor genomic testing in oncology
practice.



To understand physician and patient knowledge,
attitudes, and experiences regarding the implementation
of tumor genomic testing in oncology practice.

The MCGI has begun recruiting and enrolling patients and
physician participants at oncology practices throughout the
state. CORE’s team is working closely with their JAX
colleagues to carry out the study protocol and collect data
that will inform the implementation of tumor genomic

Graphic Source: The Jackson Laboratory 2017
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Reducing the Risks of Lung Cancer
through Prevention & Education
The Maine Lung Cancer Coalition (MLCC) is a 4-year
statewide, multi-institution, multi-disciplinary
initiative, begun in August 2016, whose goals include
improving evidence-based lung cancer prevention,
early detection, stakeholder engagement and
education, and research and data analytics to gain a
better understanding of lung cancer determinants,
disparities, and outcomes. MMCRI is the lead
institution for the Coalition, which is led by Dr. Paul
Han (Principal Investigator), Dr. Neil Korsen (Co-PI),
and Leo Waterston (Project Director). The MLCC is
funded by grants from the Bristol-Myers Squibb
Foundation and the Maine Cancer Foundation
totaling $5.4M, and in-kind support was provided by
the Maine Economic Improvement Fund. The MLCC
brings together diverse stakeholders across the entire
state to work together to reduce suffering and death
from lung cancer, with a special focus on vulnerable
rural populations with limited access to health care.

Dr. Paul Han, Leo Waterston, and Dr. Jamie Studts (University of Kentucky
Markey Cancer Center), attend the first annual MLCC Advisory Board
meeting in June.

The MLCC held its first annual Advisory Board
meeting in June 2017, at Pineland Farms in New
Gloucester, Maine. The Advisory Board members
represent key stakeholder groups in Maine, including
healthcare providers, legislators, insurers, employers,
government, and lung cancer survivors. Several MLCC
consultants also attended the meeting including
Dr. Jamie Studts, Principal Investigator of the

Kentucky LEADS Collaborative, who shared his experience
leading a similar statewide lung cancer initiative.
Lung cancer is the leading cancer killer of both men and
women in the United States, with Maine’s lung cancer rates
30% higher than the national average. The MLCC will help
to change those figures in Maine by developing, implementing
and evaluating innovative programs to increase access to lung
cancer prevention and treatment services in Maine, targeting
rural high-risk populations.

Noteworthy
As part of CORE’s partnerships with the MaineHealth Center for Performance Improvement and
the MMC Department of Medical Education,
Dr. Kathleen Fairfield helped lead the
development of a new 1-year Certificate in Health
Improvement, offered jointly through MMC and The
Dartmouth Institute for Health Policy & Clinical Practice
(TDI). The MMC-TDI Certificate Program is designed for
inter-professional teams who are willing to analyze practice
patterns and population health reports to understand
improvement opportunities. These teams will leverage
partnerships outside traditional boundaries, foster interdisciplinary teamwork, and lead the change to improve health
care delivery and population health. The program’s inaugural
cohort is currently completing the certificate, with plans for a
new cohort to enroll every year.
In partnership with the MMC Department of Medical
Education, CORE is leading the evaluation of the
(Inter-professional Partnership to Advance Care and
Education (iPACE) program, an innovative project to
redesign the clinical learning environment to improve interprofessional care and education. Funded by the “Pursuing

Excellence” initiative of the Accreditation Council for
Graduate Medical Education (ACGME), the iPACE program
aims to optimize patient-centered care; resident engagement
in patient safety and quality; provider and staff well-being and
satisfaction; and the efficiency of care and education. The
centerpiece of the program is the establishment of a new 18bed patient care unit fundamentally redesigned to foster interprofessional clinical learning and care. MMC is one of 8
premier “Pathway Innovator” institutions in the country that
was selected to participate in this ACGME
program.

3

CORE hosted seven students and trainees
over the past year, including
undergraduate, graduate, medical, and
postdoctoral trainees from around the
United States and Europe. These internships and fellowships
resulted in several peer-reviewed abstracts, publications, and
presentations at national medical conferences.

FMI

For more information about CORE go
to www.mmcri.org/core
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COMMUNITY—EDUCATION & RESEARCH SUPPORT

Education & Training

QA

Lucy Liaw, PhD, Director

An Up Close Look at
one Student’s Journey
through MMCRI

What is your connection to Maine Medical Center Research
Institute?
I first heard about MMCRI in October
of 2015 when I sat down at a guest
lecture given by Dr. Lucy Liaw at
University of Southern Maine. I had
enrolled at USM to complete a second
degree with the eventual aim of applying
to MD programs. A newcomer to
science, I had been fascinated by my
introductory courses like cellular
biology, physiology and biochemistry.
The fact that Dr. Liaw’s talk drew on
concepts from not just one but
seemingly all of these disciplines sparked
my curiosity. I attended MMCRI's open
house, and a few weeks later was welcomed to the Liaw lab as
an academic intern. I remained at the Dr. Liaw’s lab for the
following 18 months in what would prove to be my most
enriching and exciting academic experience to date. I was
fortunate enough to work not only as an intern, but
subsequently as an American Heart Association funded fellow
and finally a research assistant. In July of 2017 I left MMCRI
to begin as an MD candidate at Tufts University School of
Medicine in the Maine Track program.
Why did you seek a research position at MMCRI?
As I listened to Dr. Liaw's guest lecture in 2015, it dawned on
me that science is an unending endeavor and that her lab just
down the road at MMCRI was actively posing and exploring
new questions about the biology of blood vasculature. I was
thrilled by the idea that there were thousands of questions still
unanswered - unasked, even - building upon those
fundamental concepts I was studying at USM.
What surprised you or was unexpected about working at
MMCRI?
I was most surprised and impressed by the spirit of
mentorship, collaboration, and education guiding the work at
MMCRI. I returned to academics in 2015 after pursuing a
career as a journalist in New York, working at various
television networks over the course of six years. My
experience showed me that in many other fields and
industries work is often siloed and independent.

Above: Spencer Scott during his internship in the
Liaw laboratory prior to his entry into the
MaineTrack Medical School program.
Left: Spencer is welcomed to the TUSM-Maine
Track program by Dr. Peter Bates.

At MMCRI, not a day went by without a
colleague or mentor teaching me a new technique, sharing a
protocol or reagent, or helping me decipher data. It is that generosity
of expertise and resources that made my experience at MMCRI
invaluably enriching as a young student and researcher.
How did the experience influence your professional/career
ambitions? MMCRI exposed me to a world of biomedical research
that pushes forward the boundaries of biochemistry, genetics, and
developmental biology every day. Though I will, one day, practice
medicine as a specialized clinician, I hope that my career can
encompass research as a physician scientist. Without my experiences
at MMCRI, I might never have discovered the joys and rewards of
scientific research.

Noteworthy
MMCRI/INBRE CAREER PANEL “Exploring Graduate School and
Careers in Science, Biomedical & Health Research”, was held on May 30,
2017, and included an overview of UMaine PhD and USM MPH
programs, a career panel of 14 professionals, and a tour of MMCRI
RESPONSIBLE CONDUCT OF RESEARCH SERIES Included:
“Collaborations in Research”, "Mentoring", “The New England
Journal of Medicine Comes to Maine!”, & “Emerging Ethical
Issues in CRISPR Genome Editing”
FIELD TRIPS HOSTED Scarborough High School Gifted &
Talented Program, Greater Portland Christian School Chemistry &
Biology classes, and several high schools in Central Maine with
Gifted & Talented programs.
14

Career Development Awards for
Young Investigators
MMCRI supports the training and career development of young
professionals pursuing careers in biomedical research. These
outstanding young investigators have been successful in receiving
recognition and external funding for their research:
NIH Predoctoral Research Fellowship
Sarah McCarthy, Oxburgh Lab
To study factors involved in abnormal
development of the kidney and help find
treatment for chronic kidney disease.
NIH Postdoctoral Research Fellowships
Katie Bishop, PhD, Rosen Lab
To study the mechanism by which Dock7,
a novel therapeutic target, promotes bone
formation and couples bone remodeling in
order to develop more effective treatments
for osteoporosis.

Above: Participants in the
2017-2018 IGNITE ME
high school biomedical
research program.

Sarah Peterson, MD, PhD Sawyer/Ryzhov Lab
To investigate the role of Neuregulin/
ERBB3 signaling in resolving the systemic
inflammatory response following open
heart surgery.

Left: Humphrey Lotana, a
student at USM, participates
in a research project as part
of the SSRP.

American Heart Association Postdoctoral
Fellowship
Amanda Lessard, PhD ,Sawyer/Ryzhov Lab
To investigate the role of retinoic acid in
repair of the adult heart after cardiac
injury.

Left: MMCRI’s Summer
Student Research Program
(SSRP) Class of 2017.

American Heart Association Predoctoral
Fellowship
Jessica Davis-Knowlton, Liaw Lab
To investigate the role of vascular smooth
muscle cell Notch2 on atherogenesis and
plaque burden.
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American Heart Association Mentored
Clinical and Population Research Award
Michael Robich, MD
To study the potential beneficial effects of
resveratrol on the cardiovascular system
particularly in patients with diabetes
mellitus.
NIH Career Development Awards
Katherine Motyl, PhD
To determine the neural and skeletal
mechanisms through which a particular
protein alters bone and marrow fat
metabolism.
Elizabeth Rendina-Ruedy, PhD
To study bone metabolism in patients with
type 2 diabetes mellitus to better
understand bone biology which might
ultimately contribute to the development
of novel therapies to protect patients from
diabetic fracture.
Abby Fleisch, MD, MPH
To investigate preventable early life
determinants such as prenatal air pollution
exposure in order to better inform public
health interventions to improve early
childhood health.
Teresa May, DO
To identify cardiac arrest patients at high
risk of seizure during their ICU stay and
see if changes in their treatment will help
their brains heal.

FACTS &
FIGURES
Rotating & Fulltime
Graduate Students

10 Research Fellows
29 Academic Interns:
15 different labs & research areas
Alexa Craig, MD
To study the safety and efficacy of delayed
rewarming in neonates as a post-cardiac
surgery temperature management strategy
to improve developmental outcomes.
American Association For the Surgery of
Trauma Research Education and
Scholarship Award
Damien Carter, MD
To study the application of topical stress
signaling inhibitor on burned skin areas to
more effectively treat patients with severe
burns.
NIH Small Grant Program (R03)
Anyonya Guntur, PhD
To better understand the metabolic
pathways that control lineage allocation
and identify novel anabolic therapeutic
targets that may help in treatment of
osteoporosis.

2 International Visiting Scholars
2 MMC Medical Residents
6 Student Employees
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Enhancing the
health of our
population through
excellence in
research across the
spectrum of the
biomedical and
health sciences.
Cover Photos Front cover from Dr. Michaela
Reagan’s lab: mouse bone marrow derived
mesenchymal stem cells seeded onto silk
scaffold sponges and differentiated for 1
month in adipogenic media. Back cover (left)
from Dr. Leif Oxburgh’s lab: differentiated
human iPSC in kidney distal tubule (Brn1
expression; red) and podocytes (Podocalyxin
expression; green) after seeding in silk
scaffold.

SUPPORT OUR
RESEARCH
Maine Medical Center Research Institute
81 Research Drive ● Scarborough, ME 04074
Phone: 207-396-8181 ● www.mmcri.org
Connect with us on

MMCRI is already one of the most innovative
research organizations in the nation.
With your help, we can achieve even more.
By donating to MMCRI, you help bring the latest scientific discoveries to
the bedside and improve the quality of care patients receive. Today’s
groundbreaking study could be tomorrow’s life-saving treatment. Your
gift will help support research projects that further our understanding of
disease processes, which enables us to develop better diagnostics and
treatment.
Areas of opportunity for support of MMCRI’s laboratory-based or clinical
research projects include: Cardiovascular Disease, Cancer, Bone and
Mineral Disease, Molecular Biology and Genetics, Clinical Trials,
Psychiatric Research, and Vector Borne Diseases.
Our efforts go beyond research, as well: by supporting our summer
scholarships, you will help us educate and cultivate the next generation
of researchers, and ensure that the quest for knowledge and insight
continues for years to come.
If you’re interested in supporting the work of Maine Medical Center
Research Institute, please contact Laura Hellen of the Philanthropy
Department at (207) 662-5587 or by email at lhellen@mmc.org.
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